Ultragenyx Pharmaceutical Inc (RARE) reported disappointing financial results for the third quarter of fiscal 2025. The company's earnings per share (EPS) stood at $-1.81, falling short of the Wall Street consensus estimate of $-1.26 by $0.55. Revenue matched expectations at $0.2 billion, but the results nonetheless reflect challenges faced by the company.
The firm, which focuses on the development and commercialization of treatments for rare genetic diseases, will host an earnings conference call to discuss these results and provide further commentary on its business performance. Investors may find insights into the company's operational health and market conditions during this discussion.
Ultragenyx, headquartered in Novato, California, employs 1,294 full-time staff and is dedicated to addressing serious rare and ultrarare genetic diseases. Its product portfolio includes four approved therapies: Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). The company continues to advance its clinical pipeline with candidates such as DTX401, DTX301, UX701, and UX143, targeting various genetic disorders.
Looking ahead, Ultragenyx is scheduled to report its next earnings on August 2, 2026, with EPS estimated at $-1.1424 and revenue projected at $0.2 billion. This update provides insight into the company’s recent performance and the challenges it faces in the biotechnology sector.